Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial

OBJECTIVES: Varenicline was approved by the FDA in 2006. In 2009, based largely on case reports, the FDA issued a warning of possible adverse neuropsychiatric effects including depression and suicidal thoughts and behavior for varenicline and bupropion. Prospective trials of varenicline have not rep...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Pachas, Gladys N., Cather, Corinne, Pratt, Sarah A., Hoeppner, Bettina, Nino, Johanna, Carlini, Sara V., Achtyes, Eric D., Lando, Harry, Mueser, Kim T., Rigotti, Nancy A., Goff, Donald C., Evins, A. Eden
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3414422/
https://ncbi.nlm.nih.gov/pubmed/22888309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15504263.2012.663675
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak